AU2013308197B2 - Pyridinone compounds for use in photodynamic therapy - Google Patents

Pyridinone compounds for use in photodynamic therapy Download PDF

Info

Publication number
AU2013308197B2
AU2013308197B2 AU2013308197A AU2013308197A AU2013308197B2 AU 2013308197 B2 AU2013308197 B2 AU 2013308197B2 AU 2013308197 A AU2013308197 A AU 2013308197A AU 2013308197 A AU2013308197 A AU 2013308197A AU 2013308197 B2 AU2013308197 B2 AU 2013308197B2
Authority
AU
Australia
Prior art keywords
mal
ala
ooi
pct
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013308197A
Other languages
English (en)
Other versions
AU2013308197A1 (en
Inventor
Alison CURNOW
Alexis PERRY
Mark Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Exeter
Original Assignee
University of Exeter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Exeter filed Critical University of Exeter
Publication of AU2013308197A1 publication Critical patent/AU2013308197A1/en
Application granted granted Critical
Publication of AU2013308197B2 publication Critical patent/AU2013308197B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/81—Preparation or application process involves irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
AU2013308197A 2012-09-03 2013-09-02 Pyridinone compounds for use in photodynamic therapy Ceased AU2013308197B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1215675.8 2012-09-03
GBGB1215675.8A GB201215675D0 (en) 2012-09-03 2012-09-03 Compound
PCT/GB2013/052297 WO2014033477A1 (en) 2012-09-03 2013-09-02 Pyridinone compounds for use in photodynamic therapy

Publications (2)

Publication Number Publication Date
AU2013308197A1 AU2013308197A1 (en) 2015-04-09
AU2013308197B2 true AU2013308197B2 (en) 2018-02-01

Family

ID=47075165

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013308197A Ceased AU2013308197B2 (en) 2012-09-03 2013-09-02 Pyridinone compounds for use in photodynamic therapy

Country Status (15)

Country Link
US (1) US9346758B2 (enExample)
EP (1) EP2892881B1 (enExample)
JP (1) JP2015526499A (enExample)
KR (1) KR20150068374A (enExample)
CN (1) CN104718190B (enExample)
AU (1) AU2013308197B2 (enExample)
BR (1) BR112015004732A2 (enExample)
CA (1) CA2883754A1 (enExample)
GB (1) GB201215675D0 (enExample)
IN (1) IN2015DN02514A (enExample)
MX (1) MX2015002705A (enExample)
RU (1) RU2015111137A (enExample)
SG (1) SG11201501604TA (enExample)
WO (1) WO2014033477A1 (enExample)
ZA (1) ZA201502153B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201215675D0 (en) 2012-09-03 2012-10-17 Univ Exeter Compound
EP3148528A1 (en) 2014-06-02 2017-04-05 University of Exeter Combinations of a photosensitizer with a hydrogen sulfide donor, thioredoxin inhibitor or nitroxide for use in photodynamic therapy
CN112062713B (zh) * 2020-08-04 2023-03-31 浙江工业大学 具铁螯合性和pdt活性的ala-hpo杂合衍生物及其制备方法与应用
KR102265592B1 (ko) * 2020-10-29 2021-06-17 김진왕 5-아미노레불린산 수화염화물을 포함하는 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2269589A (en) * 1992-08-12 1994-02-16 British Tech Group 3-Hydroxypyridin-4-ones
WO2002010120A1 (en) * 2000-07-27 2002-02-07 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5895786A (en) * 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
GB201215675D0 (en) 2012-09-03 2012-10-17 Univ Exeter Compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2269589A (en) * 1992-08-12 1994-02-16 British Tech Group 3-Hydroxypyridin-4-ones
WO2002010120A1 (en) * 2000-07-27 2002-02-07 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bijaya L. Rai, et.al., Eur. J. Med. Chem., (1999-06-01), vol. 34, no. 6, pages 475 - 485 *
Emma Blake and Alison Curnow, "The Hydroxypyridinone Iron Chelator CP94 Can Enhance PpIX-induced PDT of Cultured Human Glioma Cells", Photochemistry and Photobiology, (2010-09-07), vol. 86, no. 5, pages 1154 - 1160 *

Also Published As

Publication number Publication date
ZA201502153B (en) 2017-07-26
IN2015DN02514A (enExample) 2015-09-11
EP2892881B1 (en) 2017-07-19
CN104718190B (zh) 2017-03-08
BR112015004732A2 (pt) 2018-04-17
RU2015111137A (ru) 2016-10-20
AU2013308197A1 (en) 2015-04-09
GB201215675D0 (en) 2012-10-17
EP2892881A1 (en) 2015-07-15
CA2883754A1 (en) 2014-03-06
JP2015526499A (ja) 2015-09-10
MX2015002705A (es) 2015-12-01
KR20150068374A (ko) 2015-06-19
US9346758B2 (en) 2016-05-24
US20150210642A1 (en) 2015-07-30
CN104718190A (zh) 2015-06-17
WO2014033477A1 (en) 2014-03-06
SG11201501604TA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
EP1313695B1 (en) Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US20110212955A1 (en) Rosamine derivatives as agents for the treatment of cancer
AU2002227495A1 (en) Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US20050107471A1 (en) New esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US20050171066A1 (en) Vivo use of glutathione s-transferase activated nitric oxide donors
EP2892881B1 (en) Pyridinone compounds for use in photodynamic therapy
WO2013005379A1 (ja) 光増感剤又は５－アミノレブリン酸類を用いる光線力学的治療
EP3687551B1 (en) Fluoro substituted porphyrin compounds, pharmaceutical compositions comprising the same, and methods of preparing and using the same
Gu et al. An esterase-activated diketopyrrolopyrrole-based theranostic prodrug for precise pyroptosis and synergistic chemo-photodynamic therapy of pancreatic cancer
KR102782298B1 (ko) 전이금속이 결합된 보디피계 화합물을 포함하는 초음파 감작제 조성물 및 이의 용도
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
WO2010024775A1 (en) New 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis
ES2608781T3 (es) Compuestos 3,4-bis(catecol)pirrol-N-sustituidos, su preparación y su utilización en el tratamiento del cáncer
KR20250153354A (ko) 상자성 이온이 결합된 프탈로시아닌 화합물을 포함하는 초음파 감작제 조성물 및 이의 용도
CN107043338A (zh) 一类5‑氨基酮戊酸衍生物及其制备方法和应用
WO2026053244A1 (en) Phosphorus-containing rucaparib as parp inhibitor
CA2520452A1 (en) Sapphyrins and uses thereof
IL324610A (en) Mitochondria specific transcription inhibitors
CN1526713A (zh) Combretastatin A-4磷酰胆碱类前体药物以及其合成与应用
Liu et al. Identification of a Novel and Potent Oxadiazole-Based Sphingosine Kinase 2 Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of Prostatic Cancer
ES2381951A1 (es) Derivados de aminoetanol sustituidos en c2 y su uso como antitumorales.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired